CellFX nsPFA Cardiac Surgery System to Treat Atrial Fibrillation (NANOCLAMP AF STUDY)

CellFX nsPFA Cardiac Surgery System to Treat Atrial Fibrillation (NANOCLAMP AF STUDY)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

In this study, you will have a heart procedure called an ablation using a special system called the nsPFA Cardiac Surgery System. After the procedure, you will have follow up visits at one month, three months, six months, and twelve months. Around each visit, you will wear a heart monitor to track your heart rhythm and use a phone app to share information. The study team will also collect information about your medicines and your health during the study.

Who Can Participate?

Eligibility

People can join this study if they have had atrial fibrillation and are scheduled to have planned heart surgery that is not an emergency. They cannot join if they have a pacemaker, an artificial heart valve, kidney failure, or a long term lung disease called chronic obstructive pulmonary disease.

Age Range

18-85

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

The purpose of this study is to find out if a medical system called the CellFX nsPFA Cardiac Surgery System is safe and works well to treat a heart rhythm problem called atrial fibrillation. Researchers want to learn how well this system helps fix the irregular heartbeat and keeps patients safe during and after treatment.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Pulse Biosciences’ CellFX nanosecond Pulsed Field Ablation (nsPFA) Cardiac Surgery Clamp System for treatment of Atrial Fibrillation (AF) during concomitant cardiac surgery

Principal Investigator

Adam
Williams

Protocol Number

PRO00119255

Phase

N/A

Enrollment Status

Open to Enrollment